---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-138257"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:21:48.687306+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Atea Q1 net loss $35.5M ($0.43/share); cash $620.5M; progresses bemnifosbuvir trials

## Summary
- Net loss of $35.5M ($0.43 diluted EPS) vs $42.1M ($0.51) in Q1 2022; no revenue.
- Cash, cash equivalents & marketable securities $620.5M at March 31, 2023 vs $646.7M at Dec 31, 2022.
- R&D expense $29.0M, G&A $12.6M; both roughly flat YoY; interest income rose to $6.3M.
- FDA granted Fast Track designation for bemnifosbuvir in COVID-19; Phase 3 SUNRISE-3 enrolling.
- Phase 2 HCV combination (bemnifosbuvir + ruzasvir) dosing expected 2Q23; initial data 4Q23; dengue program deprioritized.

## SEC filing metadata
- accession: 0001193125-23-138257
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312523138257/0001193125-23-138257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312523138257/d391656d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-138257
- JSON: https://secwatch.observer/filing/0001193125-23-138257.json
- Plain text: https://secwatch.observer/filing/0001193125-23-138257.txt

## Key facts
- Earnings Releases
  Atea Pharmaceuticals, Inc. reported financial results for the three months ended March 31, 2023.
  - Period: the three months ended March 31, 2023
  - Result: reported results
  source text: On May 8, 2023, Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the three months ended March 31, 2023 and other matters described in the press release.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593899/000119312523138257/0001193125-23-138257-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.